0.73
+13.85%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Rapid Micro Biosystems
From its filings with the US Securities and Exchange Commission
Rapid Micro Biosystems is based in Lexington, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker RPID. The SEC classifies its business as laboratory analytical instruments. In the fiscal year to 31 December 2025, it reported revenue of $33.6m and a net loss of $47.1m. At that date it held total assets of $74.9m and shareholders' equity of $33.2m.
We are leading a global transformation toward fully automated microbial quality control ("MQC") within pharmaceutical manufacturing. Our products safeguard the most complex and critical bioprocessing workflows in the industry, enabling faster, safer, and higher capacity drug production. Through our unique expertise at the intersection of microbiology, robotic systems, and advanced vision algorithms, we are setting the foundation for end-to-end quality control automation to enable the future of advanced pharmaceutical manufacturing.
We are an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics and cell and gene therapies, vaccines, and sterile injectables. Our flagship Growth Direct platform automates and modernizes the antiquated, manual MQC, testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct platform brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that our customers rely on to ensure safe, consistent and timely supply of important healthcare products.
Quoted from its 10-K, filed 12 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 15 Jul 2021
- Employees
- 171
- Website
- rapidmicrobio.com ↗
- Head office
- 25 HARTWELL AVENUE, LEXINGTON, MA, 02421
- Incorporated in
- DE
- Classification
- Laboratory Analytical Instruments
- Filer status
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Leadership
Pay as last reported
- Dr. Kirk MalloyIndependent Chairman of the Board$124,046
- Mr. Robert SpignesiPresident, Chief Executive Officer, Director, since 2014$1.3m
- Mr. Sean WirtjesChief Financial Officer$762,893
- Mr. John WilsonChief Operating Officer$725,767
- Mr. James XuSenior Vice President - Legal, Company Secretary
- Mr. Richard KollenderIndependent Director, since 2009$79,046
- Ms. Melinda LitherlandIndependent Director$84,046
- Ms. Inese LowensteinIndependent Director$81,546
- Mr. Natale RicciardiIndependent Director$76,546
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 30
- Environment
- 4
- Social
- 25
- Governance
- 60
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Rapid Micro Biosystems Inc possesses several strengths that contribute to its competitive advantage in the market. These include:
Weaknesses
- Despite its strengths, Rapid Micro Biosystems Inc also faces certain weaknesses that may hinder its growth and success:
Opportunities
- Several opportunities exist for Rapid Micro Biosystems Inc to further expand and enhance its business:
Threats
- Rapid Micro Biosystems Inc must address several potential threats that could impact its business negatively:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.